Company: ZVRA
Filing Date: 2025-05-08
Form Type: DEFA14A
Source: 0001193125-25-115961
Chunk: 9

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-05-08
Form: DEFA14A
Chunk 9
---
 operating company was over 25 years ago at US Wats, Inc. (“US Wats”), where he served as corporate secretary and director US Wats' stock price fell 63.9% while Regan was a director Regan's erratic nature, as seen in his online posts, could cause serious risk to Zevra’s reputation, performance, and momentum As a proxy solicitor, he was unaware of, or simply ignored, SEC solicitation rules clearly requiring him to file his online soliciting posts Regan's only other public company director-level experience was at a closed-end fund, when nominated by an activist investor During that proxy contest at Madison Strategic Sector Premium Fund, leading independent proxy advisor Glass Lewis concluded, “We see very little value in the prospective election of…Mr. Regan.” Source: Factset Research Systems Inc. Arthur Regan President and CEO of Regan & Associates -63.9% Mangless’ Nominee Arthur Regan is Unqualified For Zevra’s Board Regan Oversaw Massive Destruction of Stockholder Value as a Director on the US Wats Board US Wats, Inc. Stock Price During Arthur Regan’s Tenure (8/29/1997 to 2/11/2002)

Destroyed stockholder value while Zevra's CEO Non-independent former CEO; potentially disruptive in the boardroom Zevra shares fell 97.4% during Mickle's tenure as CEO Zevra achieved its current progress after Mickle resigned as CEO and Director in early 2023 Cannot be considered independent for several years due to his former roles as CEO until his resignation in 2023 and as a consultant until 2024 Mickle’s expertise is predominantly in drug formulation, specifically Prodrug and Ligand Activated therapy, which is not relevant to Zevra’s business or strategic priorities in this stage of its journey to become a commercial rare disease leader Highly unusual for a former CEO to return as a director so soon after departing as CEO; concern that he may seek to micromanage the executive team rather than focus on oversight, or even pursue a return to his previous role as CEO Mangless’ Nominee Travis Mickle Destroyed Stockholder Value as Zevra's CEO Travis Mickle Former President and CEO of Zevra Therapeutics Source: Factset Research Systems Inc. - 97.4% TSR During Dr. Mickle’s Tenure as CEO of Zevra (4/17/15 to 1/9/23)

Despite Zevra